CeriBell (NASDAQ:CBLL) Director Sells $720,670.56 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director William Burke sold 32,728 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $22.02, for a total transaction of $720,670.56. Following the sale, the director directly owned 17,391 shares of the company’s stock, valued at $382,949.82. This trade represents a 65.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

CeriBell Stock Performance

Shares of CBLL stock opened at $20.93 on Friday. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $29.96. The firm has a market capitalization of $776.50 million, a PE ratio of -13.86 and a beta of 1.35. The company has a 50 day moving average price of $14.32 and a 200-day moving average price of $14.51.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $22.59 million for the quarter, compared to analysts’ expectations of $21.78 million. As a group, equities research analysts expect that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Institutional Trading of CeriBell

A number of hedge funds have recently bought and sold shares of CBLL. Tower Research Capital LLC TRC boosted its stake in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell in the third quarter valued at approximately $33,000. Police & Firemen s Retirement System of New Jersey increased its holdings in CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after buying an additional 3,502 shares during the period. Finally, New York State Common Retirement Fund raised its position in CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after buying an additional 5,200 shares during the last quarter.

Analyst Ratings Changes

A number of research firms recently commented on CBLL. Raymond James Financial initiated coverage on CeriBell in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. JPMorgan Chase & Co. lowered their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. TD Cowen reduced their target price on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Finally, Cowen reaffirmed a “buy” rating on shares of CeriBell in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.17.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.